Macrophage Migration Inhibitory Factor (MIF) Concentration in the Serum of Patients with Ovarian Cysts for Differential Diagnosis of Endometrioma

자궁내막종의 감별진단을 위한 난소낭종 환자의 혈청 Macrophage Migration Inhibitory Factor (MIF) 농도의 진단적 유용성에 대한 연구

  • Kim, Man Ki (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University) ;
  • Kim, Yu Re (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University) ;
  • Hong, Seong Hwa (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University) ;
  • Park, Yeon Jin (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University) ;
  • Ji, IL Woon (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University) ;
  • Jeong, Eun Hwan (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University) ;
  • Kim, Hak Soon (Department of Obstetrics and Gynecology, College of Medicine Chungbuk National University)
  • 김만기 (충북대학교 의과대학 산부인과학교실) ;
  • 김유래 (충북대학교 의과대학 산부인과학교실) ;
  • 홍승화 (충북대학교 의과대학 산부인과학교실) ;
  • 박연진 (충북대학교 의과대학 산부인과학교실) ;
  • 지일운 (충북대학교 의과대학 산부인과학교실) ;
  • 정은환 (충북대학교 의과대학 산부인과학교실) ;
  • 김학순 (충북대학교 의과대학 산부인과학교실)
  • Published : 2005.09.30

Abstract

Objective: To evaluate the usefulness of serum concentrations of macrophage migration inhibitory factor (MIF) of patients with ovarian cysts for differential diagnosis of endometrioama. Method: From Jan. 2003 to Dec. 2004, preoperative serum MIF levels were assessed in 28 women with endometrioma, 32 with benign epithelial tumor, 23 with functional and simple cysts, 22 with benign mature cystic teratoma, and 25 women without ovarian tumor as control. MIF levels were determined using an ELISA (Quantikine Human MIF immunoassay, R&D Systems, Inc., USA). Results: Mean MIF levels were higher in all groups with benign tumors than control (all p<0.01), but there was no significant difference between benign tumor groups (p=0.95). There was no significant correlation between MIF levels and tumor volume, body mass index (BMI) (p=0.635, 0.674 respectively) Serum MIF level had significant correlation with count of WBC and neutrophils (p=0.008, 0.024 respectively), but had no correlation with count of lymhocytes and monocytes (p=0.688, 0.294 respectively). Conclusions: This study showed a marked increase in MIF concentrations in the peripheral blood of patients with endometrioma, but there was no significant difference with other benign tumors. Serum MIF level had significant correlation with count of WBC and neutrophils. These suggest serum MIF level has no usefulness for differential diagnosis of endometrioma from other benign ovarian cysts.

Keywords

References

  1. Morand EF. New therapeutic targetin inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005; 35:419-26 https://doi.org/10.1111/j.1445-5994.2005.00853.x
  2. Donn RP, Ray DW. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004; 182: 1-9 https://doi.org/10.1677/joe.0.1820001
  3. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innateimmunity. Nat Rev Immunol 2003; 3: 791-800 https://doi.org/10.1038/nri1200
  4. Baugh JA, Donnelly SC. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronicinflammation. J Endocrinol 2003; 179: 15-23 https://doi.org/10.1677/joe.0.1790015
  5. Paul Dmowski W, Braun DP. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol 2004; 18: 245-63 https://doi.org/10.1016/j.bpobgyn.2004.02.001
  6. Kyama CM, Debrock S, Mwenda JM, D'Hooghe TM. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 2003; 1: 123-31. https://doi.org/10.1186/1477-7827-1-123
  7. Berkkanoglu M, Arici A. Immunology and endometriosis. Am J Reprod Immunol 2003; 50: 48-59 https://doi.org/10.1034/j.1600-0897.2003.00042.x
  8. Kats R, Collette T, Metz CN, Akoum A. Marked elevation of macrophage migration inhibitory factor in the peritoneal fluid of women with endometriosis. Fertil Steril 2002; 78: 69-76 https://doi.org/10.1016/S0015-0282(02)03189-8
  9. Kats R, Metz CN, Akoum A. Macrophage migration inhibitory factor is markedly expressed in active and early-stage endometriotic lesions. J Clin Endocrinol Metab 2002; 87: 883-9 https://doi.org/10.1210/jc.87.2.883
  10. Morin M, Bellehumeur C, Therriault MJ, Metz C, Maheux R, Akoum A. Elevated levels of macrophage migration inhibitory factor in the peripheral blood of women with endometriosis. Fertil Steril 2005; 83: 865-72 https://doi.org/10.1016/j.fertnstert.2004.10.039
  11. Brosens J, Timmerman D, Starzinski-Powitz A, Brosens I. Noninvasive diagnosis of endometriosis: the role of imaging and markers. Obstet Gynecol Clin North Am 2003; 30: 95-114 https://doi.org/10.1016/S0889-8545(02)00055-4
  12. Bedaiwy MA, Falcone T. Laboratory testing for endometriosis. Clin Ch im Acta 2004; 340: 41-56 https://doi.org/10.1016/j.cccn.2003.10.021
  13. Moore J, Copley S, Morris J, Lindsell D, Golding S, Kennedy S. A systematic review of the accuracy of ultrasound in the diagnosis of endometriosis. Ultrasound Obstet Gynecol 2002; 20: 630-4 https://doi.org/10.1046/j.1469-0705.2002.00862.x
  14. de Kroon CD, van der Sandt HA, van Houwelingen JC, Jansen FW. Sonographic assessment of nonmalignant ovarian cysts: does sonohistology exist? Hum Reprod 2004; 19: 2138-43 https://doi.org/10.1093/humrep/deh353
  15. Todros T, Bontempo S, Piccoli E, Ietta F, Romagnoli R, Biolcati M, et al. Increased levels of macrophage migration inhibitory factor (MIF) in preeclampsia. Eur J Obstet Gynecol Reprod Biol In press 2005
  16. Ietta F, Tadros T, Ticconi C, Piccoli E, Zicari A, Piccione E, et al. Macrophage migration inhibitory factor in human pregnancy and labor. Am J Reprod Immunol 2002;48:404-9 https://doi.org/10.1034/j.1600-0897.2002.01152.x
  17. Church TS, Willis MS, Priest EL, Lamonte MI, Earnest CP, Wilkinson WJ, et al. Obesity, macrophage migration inhibitory factor, and weight loss. Int J Obes Relat Metab Disord 2005; 29: 675-81 https://doi.org/10.1038/sj.ijo.0802942
  18. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45-55 https://doi.org/10.1093/humupd/6.1.45
  19. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996; 98: 482-9 https://doi.org/10.1172/JCI118815
  20. Dmowski WP, Gebel HM, Braun DP. The role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand Suppl 1994; 159: 7-14
  21. Gebel HM, Braun DP, Tarnbur A, Frame D, Rana N, Dmowski WP. Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. Fertil Steril 1998; 69: 1042-7 https://doi.org/10.1016/S0015-0282(98)00073-9
  22. Braun DP, Muriana A, Gebel H, Rotman C, Rana N, Dmowski WP. Monocyte-mediated enhancement of endometrial cell proliferation in women with endometriosis. Fertil Steril 1994; 61: 78-84